Cost-benefit analysis of sheep and goat brucellosis vaccination with Rev.1 in the north of Portugal from 2000 to 2005 / Análise de custo-benefício da vacinação com Rev.1 da brucelose ovina e caprina no norte de Portugal entre 2000 e 2005

In the North of Portugal, a mass vaccination programme of small ruminants was conducted from 2001 to 2004. A study of cost-benefit was carried out for the 2000/2005 period to ascertain the economic benefits of this strategy. In order to estimate the cost of the zoonosis, the compensation costs paid to farmers for culled animals in the Brucellosis Eradication Campaign, data from vaccine Rev. 1 costs, and costs of people internment due to brucellosis were studied. An increase in the cost was observed from 2000 to 2001 (aproximately US$ 110,000), essentially due to compensation for culled animals, but also from vaccination and human internment costs. However, a progressive decrease was observed from 2001 to 2004 (from more than US$1,200,000 in 2001 to US$180,000 in 2004), roughly US$ 1,020,000 less. As the main conclusion, the annual cost of this zoonosis decreased by an average of almost US$600,000 per year, and a total of more than three million dollars were saved from 2000 to 2005. The results of this study suggest that mass vaccination with Rev. 1 reduced overall costs and was effective in reducing animal and human brucellosis costs.(AU)

No norte de Portugal, procedeu-se à vacinação massiva contra a brucelose em pequenos ruminantes entre 2001 e 2004. Neste estudo, efetuou-se uma análise de custo benefício entre 2000 e 2005 para apurar os benefícios econômicos dessa estratégia. Para estimar o custo da zoonose, estudaram-se três variáveis: a indenização paga aos proprietários dos animais eliminados durante a campanha de erradicação da brucelose, o custo da vacina Rev. 1 e os custos de internamento das pessoas infectadas por brucelose nas unidades de Serviços de Saúde. Durante os anos em estudo, observou-se um aumento de custo de aproximadamente US$110.000, entre 2000 e 2001, principalmente, devido à indenização dos animais eliminados e à aplicação da vacina e os custos por internamento de pessoas infectadas, seguindo-se uma redução acentuada entre 2001 e 2004 (de US$1.200.000 para US$180.000 em 2004), o que perfez US$1.020.000 poupados. O custo anual da zoonose, em relação às variáveis estudadas, diminuiu em média US$600.000 por ano, sendo poupados mais de US$ 3.000.000 entre 2000 e 2005. Estes resultados sugerem que a vacinação com Rev. 1 reduziu os custos totais da infecção humana e animal relativamente às variáveis estudadas.(AU)

Resposta imunitária à vacinação conjuntival com a estirpe Rev.1 de Brucella melitensis em ovinos e caprinos / Serological response of sheep and goats to conjunctival Brucella melitensis Rev.1 vaccine

The live B. melitensis Rev.1 strain is considered the best vaccine available for the prophylaxis of brucellosis in small ruminants, especially when used at the standard dose by the conjunctival route. In the present study a 1´ 109 CFU dose for both sheep and goats conjunctivally vaccinated was tested to evaluate the duration of serological responses. Conjunctival vaccination with Rev. 1 performed in adult animals induced a rapid rise in serological titres as measured by Rose Bengal Plate Test (RBPT), Complement Fixation Test (CF) and Modified Rose Bengal Plate Test (MRBPT). Titres then decreased and became negative in most animals by four months after vaccination (except MRBPT). The goats responded better to the vaccination than the sheep as one month after vaccination 100% of the goats revealed positive results to RB and RBM and 93.4% to FC test. The RBM was the one that detected more positive animals along the study.(AU)